San Diego-based Viking Therapeutics marked itself as a serious competitor from the weight loss drug current market in February right after revealing promising information from a mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when specified to be a weekly injection and in March the co